Centre for Human Drug Research

𝐂𝐇𝐃𝐑 𝐳𝐨𝐞𝐤𝐭 𝐞𝐞𝐧 𝐀𝐫𝐭𝐬-𝐎𝐧𝐝𝐞𝐫𝐳𝐨𝐞𝐤𝐞𝐫 / 𝐏𝐡𝐃 𝐬𝐭𝐮𝐝𝐞𝐧𝐭 𝐍𝐞𝐮𝐫𝐨𝐥𝐨𝐠𝐢𝐞 🩺🧠 Ben jij (bijna) afgestudeerd als arts en op zoek naar een uitdaging die je carrière zowel professioneel als persoonlijk verder helpt? Bij CHDR krijg je de kans om je te ontwikkelen in een dynamische omgeving waar wetenschap en het bedrijfsleven samenkomen. Als arts-onderzoeker werk je mee aan baanbrekend onderzoek in de neurologie, waaronder Parkinson. Klaar voor de volgende stap? Ontdek de mogelijkheden bij CHDR! 𝗪𝗮𝘁 𝗴𝗮 𝗷𝗲 𝗱𝗼𝗲𝗻? ✔️Je gaat werken aan medicijnontwikkeling binnen de neurologie, met focus op spierziekten, Parkinson, ALS en neuronale excitabiliteit; ✔️Je bereidt het onderzoek voor, coördineert de uitvoering, analyseert de resultaten en publiceert de bevindingen; ✔️Je bezoekt (inter)nationale congressen. 𝗪𝗮𝘁 𝗯𝗶𝗲𝗱𝘁 𝗖𝗛𝗗𝗥 𝗷𝗼𝘂? ✔️ Een passend salaris tussen €4100,00 - €4500,00 (o.b.v. expertise); ✔️ 8% vakantietoeslag, eindejaarsuitkering, 25 vakantiedagen en een diversiteitsdag; ✔️ Je krijgt de mogelijkheid om je te certificeren tot klinisch farmacoloog (certificering via NVKFB). 𝐄𝐧𝐭𝐡𝐨𝐮𝐬𝐢𝐚𝐬𝐭 𝐠𝐞𝐰𝐨𝐫𝐝𝐞𝐧? Solliciteer direct via https://lnkd.in/eg35fKnV of neem contact op met Trix Kuijken via 06 44 40 56 29! #CHDR #centreforhumandrugresearch #artsonderzoeker #neurologie #PhD

𝐂𝐇𝐃𝐑 𝐳𝐨𝐞𝐤𝐭 𝐞𝐞𝐧 𝐀𝐫𝐭𝐬-𝐎𝐧𝐝𝐞𝐫𝐳𝐨𝐞𝐤𝐞𝐫 𝐃𝐞𝐫𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐢𝐞 & 𝐈𝐦𝐦𝐮𝐧𝐨𝐥𝐨𝐠𝐢𝐞! 🩺 Wil jij als arts-onderzoeker een sleutelrol spelen in innovatief geneesmiddelonderzoek binnen de dermatologie? Bij CHDR krijg je de kans om baanbrekende immunologische behandelingen te onderzoeken en direct bij te dragen aan de ontwikkeling van nieuwe therapieën. Ben jij klaar om jezelf te ontwikkelen als expert in klinisch onderzoek en impact te maken op de toekomst van de gezondheidszorg? 𝗪𝗮𝘁 𝗴𝗮 𝗷𝗲 𝗱𝗼𝗲𝗻? ✔️ Je vervult een brugfunctie tussen CHDR’s klinische derma-immunologiegroep en het R&D-laboratorium; ✔️ Je bereidt het onderzoek voor, coördineert de uitvoering, analyseert de resultaten en publiceert de bevindingen; ✔️ Je bezoekt (inter)nationale congressen. 𝗪𝗮𝘁 𝗯𝗶𝗲𝗱𝘁 𝗖𝗛𝗗𝗥 𝗷𝗼𝘂? ✔️ Een passend salaris tussen €4100,00 - €4500,00 (o.b.v. expertise); ✔️ 8% vakantietoeslag, eindejaarsuitkering, 25 vakantiedagen en een diversiteitsdag; ✔️ Een opleiding tot klinisch farmacoloog (certificering via NVKFB). Enthousiast geworden? Solliciteer direct via https://lnkd.in/ezydTrDx of neem contact op met Trix Kuijken via 06 44 40 56 29! #CHDR #centreforhumandrugresearch #artsonderzoeker #dermatologie #Immunologie

At CHDR, we are proud to participate in the global EURORDIS "Light Up for Rare" campaign in celebration of Rare Disease Day 2025. This year, the Leiden Bio Science Park will join this important initiative by illuminating buildings across the park, including CHDR, to raise awareness for the rare disease community. We are committed to supporting groundbreaking research and fostering innovation for rare diseases. By taking part in this campaign alongside other organisations at the park, we amplify the voices of those affected and highlight the need for patient-centered solutions in drug development. Together, we can shine a light on the importance of rare disease research and patient inclusion. Learn more at https://lnkd.in/gk6hbAF #LightUpForRare #RareDiseaseDay

As cannabis use and cannabis potency increases globally, so do emergency department visits due to cannabinoid-induced toxicity, including acute cannabinoid intoxication (ACI). Currently, there are no approved therapies available for targeted treatment of cannabinoid-induced toxicity.   In a study conducted in collaboration with Anebulo Pharmaceuticals and Verdient Science, LLC, we investigated the potential of CB1 receptor antagonist selonabant (ANEB-001) to block the effects of Δ9-tetrahydrocannabinol (THC) in healthy volunteers. Our findings demonstrated that selonabant significantly reduced typical THC effects on feeling high, alertness and postural stability compared to placebo. Furthermore, single doses of selonabant were safe and well tolerated.   These results highlight the potential of selonabant as a promising emergency treatment for ACI, a growing concern in light of expanding cannabis legalization.   Read more in our new publication in Clinical Pharmacology & Therapeutics: https://lnkd.in/eyausvKP #ClinicalResearch #Cannabis #THC

As we previously shared, CHDR is expanding to Twente, and we're thrilled to share the next exciting step in this journey! We are proud to announce the appointment of Rozemarije Holewijn as the new Director of CHDR Twente. With her background as a neurosurgeon, Rozemarije brings significant expertise in innovative healthcare and scientific research. Her experience leading multidisciplinary teams in challenging environments will be invaluable in this new and exciting role. This marks another milestone in our collaboration with Medisch Spectrum Twente and TechMed Centre - University of Twente. Together, we aim to drive forward cutting-edge drug research, enhance patient outcomes, and create new opportunities in the region for research, education, and entrepreneurship. We look forward to the continued growth and success of CHDR Twente under Rozemarije’s leadership, and we’re excited for the impact this will have on the future of drug research and healthcare! #ClinicalResearch #ClinicalTrials #InnovationInHealthcare

We are proud to present our 2024 Highlights Report! 2024 was a transformative year at CHDR, marked by new leadership, groundbreaking research, and significant milestones. We celebrated a record number of PhD and Clinical Pharmacology graduates, expanded our capabilities with a new site in Twente, and received recognition for our contributions to drug development and innovation. This report offers a glimpse into the key achievements across our research areas, showcasing a year of progress, collaboration, and growth. #DrugDevelopment #ClinicalResearch #Biomarkers #Innovation

Exciting News: first PhD Graduate of 2025! On January 10, Salma Assil successfully defended her PhD thesis on pharmacological challenge models. Salma’s work focuses on the Imiquimod (IMQ) challenge model, which mimics psoriasiform lesions and activates immune pathways relevant to human disease. By systematically optimizing the IMQ model, benchmarking with anti-inflammatory agents, and conducting proof-of-mechanism studies, her thesis demonstrates how the IMQ model can be implemented in clinical research. This approach has the potential to improve drug development by accelerating timelines, enhancing efficiency, and reducing costs. Congratulations, Salma, on this milestone and for driving innovation forward in 2025! Find out more here: https://lnkd.in/eTiy7C7u #PhD #DrugDevelopment #Inflammation #Pharmacology #Innovation

𝗗𝗿𝗮𝗮𝗴 𝗯𝗶𝗷 𝗮𝗮𝗻 𝗸𝗹𝗶𝗻𝗶𝘀𝗰𝗵𝗴𝗲𝗻𝗲𝗲𝘀𝗺𝗶𝗱𝗱𝗲𝗹𝗲𝗻𝗼𝗻𝗱𝗲𝗿𝘇𝗼𝗲𝗸! 🩺 Wil jij talent verbinden met innovatie en impact maken in de zorg en wetenschap? Als Recruiter bij het Centre for Human Drug Research speel je een cruciale rol in het vinden van topkandidaten, van artsen tot IT-specialisten. Jij zorgt voor de perfecte match en versterkt ons werkgeversmerk.   𝗪𝗮𝘁 𝗴𝗮 𝗷𝗲 𝗱𝗼𝗲𝗻? ✔️ Ons sollicitatieproces runnen van A - Z, het coördineren van gesprekken tot het voeren van sollicitaties; ✔️ Talent vinden en enthousiasmeren via LinkedIn Recruiter en andere sourcingmethoden; ✔️ Employer branding versterken, zodat we een aantrekkelijke werkgever blijven.   𝗪𝗮𝘁 𝗯𝗶𝗲𝗱𝘁 𝗖𝗛𝗗𝗥 𝗷𝗼𝘂? ✔️ Een passend salaris tussen €3.000 - €4.000 (o.b.v. 40 uur); ✔️ Pensioenopbouw bij het ABP waar CHDR 70% van de Pensioenbijdrage betaalt; ✔️ 8% vakantietoeslag, eindejaarsuitkering, 25 vakantiedagen en een diversiteitsdag.   𝗪𝗮𝘁 𝗯𝗿𝗲𝗻𝗴 𝗷𝗲 𝗺𝗲𝗲? ✔️ Minimaal 2 jaar werkervaring in Recruitment; ✔️ Sterke communicatie en gestructureerd werken; ✔️ Affiniteit met zorg of klinisch onderzoek.   Enthousiast geworden? Solliciteer direct via https://lnkd.in/e9EddAkT of neem contact op met Marit Beets via 06 25 58 76 98!   #CHDR #centreforhumandrugresearch #Recruiter #Recruitment

We are excited to end the year on a high note with a double publication in Clinical Pharmacology & Therapeutics! These publications emphasize the significant role of neurophysiological excitability biomarkers in early-phase drug development. In collaboration with Trevena, Inc.. and NMD Pharma A/S, we conducted two early-phase clinical trials, employing two excitability biomarkers: 🧠Cortical Excitability Using Transcranial Magnetic Stimulation and pharmaco-EEG, we demonstrated CNS target engagement and temporal effects of TRV045, a selective Sphingosine-1-Phosphate Subtype 1 Receptor agonist being developed for epilepsy. 💪Muscle Excitability Using Muscle Velocity Recovery Cycles, we showed direct target engagement and increased muscle excitability following treatment with NMD670, a ClC-1 inhibitor under development for muscle weakness in neuromuscular diseases. These studies underscore the power of biomarker-driven strategies. They showcase the synergy between developing innovative biomarkers and novel drugs with unique mechanisms of action, pushing the boundaries of our understanding of these physiological processes. We sincerely thank all our collaborators and study participants, without whom these studies would not have been possible. 📖 Read more about these exciting developments in our publications: https://lnkd.in/eKrsUyVp https://lnkd.in/e9sfW86J If you want to know more about the excitability methods we use in our early phase clinical drug trails, please follow the link to our brochure: https://lnkd.in/eT4xhcR7 #DrugDevelopment #ClinicalResearch #Biomarkers #Innovation #Excitability

Happy holidays!🎄⭐ As the year comes to a close, we would like to extend our heartfelt thanks to our study participants, partners, and colleagues for their invaluable contributions to advancing clinical research. We wish you and your loved ones a joyful Christmas, filled with warmth and happiness. May the New Year bring you health and success, and we look forward to continuing our collaboration towards better patient outcomes in the year ahead.